VolgendeVolgende gids
AI in batterijontwerp en -optimalisatie
Toepassingen
ToepassingenGIDS
AI methods can predict protein structures, propose backbones, and help select sequences.
Luister naar deze gidsAI-verteld · ~2 min
These are research tools: predicted structure or designed sequence alone does not establish biological function, therapeutic effect, safety, or clinical readiness.
AlphaFold predicts protein structures from sequence, while methods such as RFdiffusion propose protein backbones and ProteinMPNN predicts sequences compatible with a target backbone. The cited RFdiffusion and ProteinMPNN studies report particular computational and laboratory evaluations; their results do not establish that any generated candidate is functional or suitable as a medicine. Antibody CDR loops contribute to antigen binding, but successful binding, specificity, developability, and safety require experimental evaluation. AlphaFold 3’s developer description includes modeling interactions involving proteins, DNA, RNA, small molecules, ions, and modified residues; predictions remain research hypotheses. For a therapeutic biologic intended for human use and marketing in the United States, FDA describes preclinical and clinical development and applicable marketing review; recombinant therapeutic proteins may require a biologics license application. This pathway does not apply to every research protein or to non-therapeutic structures. AlphaFold-Multimer is a separate model variant developed for predicting structures of multiple interacting protein chains; those predictions are hypotheses that require experimental assessment. The associated primary paper reports improved interface prediction in its evaluated settings.
AlphaFold’s 2020 publication describes protein-structure prediction from amino-acid sequence.
RFdiffusion’s paper evaluates computationally designed protein structures and selected experimental validations.
ProteinMPNN predicts sequences for target backbone structures in reported design experiments.
Illustrative: researchers may test candidate antibody loops experimentally; no design method guarantees binding or therapeutic performance.
A useful research direction is to measure how computational design success transfers to expression, stability, binding, and functional assays. Therapeutic development requires product-specific evidence and the applicable regulatory pathway; do not infer clinical benefit from a computational design result.
Gratis nieuwsbrief
Drie verifieerde AI-verhalen elke weekdagmorgen, geschreven in eenvoudig Engels. Gratis voor altijd, geen advertenties.
Eén e-mail elke weekdag. Afmelden met één klik. We verkopen of delen je adres nooit.
Test jezelf
Directe feedback op elke antwoord, en een deelbare certificaat met een verifieerbare ID zodra je een cursus hebt afgerond.
Ondersteun gratis AI-onderwijs. AI Understanding is een 501(c)(3) non-profit — geen advertenties, geen betaalmuur, nooit. Doe een donatie
AI methods can predict protein structures, propose backbones, and help select sequences. These are research tools: predicted structure or designed sequence alone does not establish biological function, therapeutic effect, safety, or clinical readiness.
AlphaFold heeft een doorbraak bereikt in het voorspellen van de 3D-structuur van een eiwit op basis van de aminozuursequentie.
RFdiffusion maakt gebruik van een diffusiemodel om geheel nieuwe eiwitskeletten te ontwerpen, vaak geconditioneerd op een bindend doelwit.
ProteinMPNN is an inverse-folding model: it predicts candidate sequences for a specified backbone. A prediction does not guarantee that a sequence will fold or function experimentally.
AI helpt bij het ontwerpen van de complementariteitsbepalende regio's (CDR's), de lussen die zich hechten aan een doelantigeen.
Protein structure is related to function, but structure predictions and design hypotheses do not replace biochemical or functional assays.
Blijf leren
Er zijn meer handleidingen voor dit onderwerp geselecteerd
VolgendeVolgende gids
AI in batterijontwerp en -optimalisatie
Toepassingen